Missed rifampicin and isoniazid resistance by commercial molecular assays
| dc.contributor.author | Richards, L. | |
| dc.contributor.author | Ismail, Farzana | |
| dc.contributor.author | Nel, J. | |
| dc.contributor.author | Omar, Shaheed Vally | |
| dc.date.accessioned | 2025-06-25T12:12:25Z | |
| dc.date.available | 2025-06-25T12:12:25Z | |
| dc.date.issued | 2024-07 | |
| dc.description.abstract | Drug-resistant tuberculosis (TB) has poor outcomes unless resistance is detected early, ideally by commercially available molecular tests. We present a case of occult multidrug-resistant TB where both rifampicin and isoniazid resistance were missed by molecular testing and were only identified by phenotypic testing. | |
| dc.description.department | Medical Microbiology | |
| dc.description.librarian | am2025 | |
| dc.description.sdg | SDG-03: Good health and well-being | |
| dc.description.uri | http://www.samj.org.za/index.php/samj | |
| dc.identifier.citation | Richards, L., Ismail, F., Nel, J. et al. 2024, 'Missed rifampicin and isoniazid resistance by commercial molecular assays', South African Medical Journal, vol. 114, no. 7, pp. 14-16. https://doi.org/10.7196/SAMJ.2024.v114i7.1779. | |
| dc.identifier.issn | 0256-9574 (print) | |
| dc.identifier.issn | 2078-5135 (online) | |
| dc.identifier.other | 10.7196/SAMJ.2024.v114i7.1779 | |
| dc.identifier.uri | http://hdl.handle.net/2263/102997 | |
| dc.language.iso | en | |
| dc.publisher | South African Medical Association | |
| dc.rights | © 2024 L Richards, F Ismail, J Nel, S V Omar. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. | |
| dc.subject | Tuberculosis (TB) | |
| dc.subject | Drug resistance | |
| dc.subject | Diagnosis | |
| dc.subject | Mutations | |
| dc.subject | Molecular markers | |
| dc.subject | Challenges | |
| dc.subject | Drug-resistant tuberculosis (DR-TB) | |
| dc.title | Missed rifampicin and isoniazid resistance by commercial molecular assays | |
| dc.type | Article |